This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): isavuconazole prodrug, BAL8557, isavuconazonium chloride, BAL4815
BAL8557 is a novel broad-spectrum azole prodrug that can be given orally and intravenously with the potential to treat mucocutaneous and invasive fungal infections, and fungal infections of the nail.
The azole antifungals inhibit the cytochrome P450 (CYP)-dependent enzyme, 14-a-demethylase. This inhibition disrupts membrane synthesis resulting in depletion of ergosterol and leads to accumulation of toxic sterol precursors.
Basilea and Astellas
In February 2010, Basilea announced that it entered into a license, co-development and co-promotion agreement with Astellas Pharma for Basilea's isavuconazole on a worldwide basis, including an option for Japan.
Under the terms of the agreement, Basilea will receive an upfront payment of CHF 75 million and will be eligible to receive up to CHF 478 million in additional payments on achievement of pre-specified development and sales milestones. Basilea will also receive significant double-digit tiered royalties on sales.
Astellas is granted an exclusive right to commercialize isavuconazole whereas Basilea retains an option to co-promote the product in the United States, Canada, major European countries and the People's Republic of China. Basilea and Astellas will jointly participate in the development of isavuconazole. Astellas will lead the development and contribute the majority of the investments required for completing the clinical...See full deal structure in Biomedtracker
Partners: Basilea Pharmaceutica AG Hikma Pharmaceuticals plc Biotoscana International Asahi Kasei Corporation
Additional information available to subscribers only: